GENEDRIVE PLC (GDR) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the GENEDRIVE PLC full year results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time via the q and a tab that's just situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and we'll publish those responses where it is appropriate to do so. And before we begin, as usual, we would just like to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the executive management team from GENEDRIVE PLC. Gino, good afternoon, sir. Good afternoon, and thank you everyone for joining us today. I'm Gino. I'm the CEO of GENEDRIVE. So I was appointed in August 2024, and but I've been with the company in its various incarnation since 2011. So very much behind the development of the instrument, the assays, and tests that we put on that instrument and and the positioning of our company into what we call pharmacogenetic testing. And I'm joined by, our CFO, Russ Shaw. Russ, do you want to introduce yourself? Thank you, Gino. Yeah. I'm Russ Shaw, CFO. I've been with GENEDRIVE since April 22. I've got twenty five years international experience in high growth companies across multiple sectors, including life sciences, diagnostics, technology, and industrials. Predominantly, a name quoted companies, I've also been CFO of, private businesses as well. Okay. Thanks, Ross. Okay. So what I'd like to do today is here's ...